<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00891436</url>
  </required_header>
  <id_info>
    <org_study_id>RUMCgsk 113002</org_study_id>
    <nct_id>NCT00891436</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms</brief_title>
  <official_title>Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale and objectives:

      Fluticasone furoate nasal spray (Veramyst) has been shown to improve ocular symptoms when
      used for the treatment of seasonal allergic rhinitis during the ragweed pollen season.
      Although this is the only published report of an intranasal corticosteroid shown to
      effectively treat ocular symptoms, the mechanism has not been delineated. Furthermore, the
      tears of patients with allergic conjunctivitis are known to have increased concentrations of
      cytokines and allergic mediators.

      The objective of this study is to determine if the positive effects of Veramyst nasal spray
      on ocular symptoms is via the inhibition of allergic mediators in the eyes. The investigators
      will conduct a double blind placebo controlled trial to determine if Veramyst nasal spray
      decreases the amount of allergic mediators in the tears of subjects randomized to Veramyst
      nasal spray versus placebo. The investigators will also compare the subjects' symptoms to the
      amount of allergic mediators detected in their tears.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eosinophilic Cationic Protein (ECP) Levels</measure>
    <time_frame>Samples taken at initial visit &amp; 2 week follow-up</time_frame>
    <description>Tear samples from the participants eyes were collect and were to be used for measuring esinophilic cationic prtein, but this was not measured because the volume of tears were to low.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histamine Content in the Tears Was Measured.</measure>
    <time_frame>Samples taken at initial visit &amp; 2 week follow-up</time_frame>
    <description>Tear samples were assayed for histamine by ELISA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Allergic Conjunctivitis to Tree Pollen or Grass Pollen</condition>
  <arm_group>
    <arm_group_label>Placebo nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone furoate nasal spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone furoate nasal spray</intervention_name>
    <description>2 sprays each nostril every morning for 2 weeks</description>
    <arm_group_label>Fluticasone furoate nasal spray</arm_group_label>
    <other_name>Veramyst</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo nasal spray</intervention_name>
    <description>2 sprays each nostril every morning for 2 weeks</description>
    <arm_group_label>Placebo nasal spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a documented history of allergic rhinitis and conjunctivitis due to tree pollen and /
             or grass pollen for two allergy seasons

          -  positive skin prick test to tree and / or grass

        Exclusion Criteria:

          -  glaucoma

          -  cataracts

          -  acute or chronic sinusitis

          -  asthma

          -  chronic obstructive pulmonary disease

          -  physical nasal obstruction

          -  pregnant or breastfeeding

          -  have had a viral or bacterial infections within 2 weeks of the study commencement

          -  receiving allergen immunotherapy

          -  have used inhaled corticosteroids within 14 days prior to the study

          -  have used systemic corticosteroids within 30 days of the study

          -  travel outside of the geographic area during the 2 week study period

          -  use of contact lenses during the study period

          -  use of artificial tears during the study period

          -  use of eyewash irrigation during the study period

          -  use of lubricants during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Moy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2009</study_first_submitted>
  <study_first_submitted_qc>April 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2009</study_first_posted>
  <results_first_submitted>September 14, 2012</results_first_submitted>
  <results_first_submitted_qc>September 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 18, 2012</results_first_posted>
  <last_update_submitted>November 29, 2012</last_update_submitted>
  <last_update_submitted_qc>November 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>James Moy</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited during the spring pollen season of 2009 at a large urban medcial center's allergy clinic.</recruitment_details>
      <pre_assignment_details>There was no run in period. All 20 participants that enrolled in this study were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fluticasone Furoate Nasal Spray</title>
          <description>Fluticasone furoate nasal spray : 2 sprays each nostril every morning for 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo Nasal Spray</title>
          <description>Placebo nasal spray : 2 sprays each nostril every morning for 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluticasone Furoate Nasal Spray</title>
          <description>Fluticasone furoate nasal spray : 2 sprays each nostril every morning for 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo Nasal Spray</title>
          <description>Placebo nasal spray : 2 sprays each nostril every morning for 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="7.3"/>
                    <measurement group_id="B2" value="29" spread="8.0"/>
                    <measurement group_id="B3" value="30" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Eosinophilic Cationic Protein (ECP) Levels</title>
        <description>Tear samples from the participants eyes were collect and were to be used for measuring esinophilic cationic prtein, but this was not measured because the volume of tears were to low.</description>
        <time_frame>Samples taken at initial visit &amp; 2 week follow-up</time_frame>
        <population>Tear samples from the participants eyes were collect and were to be used for measuring esinophilic cationic prtein, but this was not measured because the volume of tears were to low.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Furoate Nasal Spray</title>
            <description>Fluticasone furoate nasal spray : 2 sprays each nostril every morning for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo nasal spray : 2 sprays each nostril every morning for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Eosinophilic Cationic Protein (ECP) Levels</title>
          <description>Tear samples from the participants eyes were collect and were to be used for measuring esinophilic cationic prtein, but this was not measured because the volume of tears were to low.</description>
          <population>Tear samples from the participants eyes were collect and were to be used for measuring esinophilic cationic prtein, but this was not measured because the volume of tears were to low.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Histamine Content in the Tears Was Measured.</title>
        <description>Tear samples were assayed for histamine by ELISA</description>
        <time_frame>Samples taken at initial visit &amp; 2 week follow-up</time_frame>
        <population>All participants had tears measured for histamine.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Furoate Nasal Spray</title>
            <description>Fluticasone furoate nasal spray : 2 sprays each nostril every morning for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo nasal spray : 2 sprays each nostril every morning for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Histamine Content in the Tears Was Measured.</title>
          <description>Tear samples were assayed for histamine by ELISA</description>
          <population>All participants had tears measured for histamine.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="0.9"/>
                    <measurement group_id="O2" value="5.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>paired t-test was used for the data analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.1</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>t-test showed no different between the 2 groups.</non_inferiority_desc>
            <p_value>&gt;0.1</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fluticasone Furoate Nasal Spray</title>
          <description>Fluticasone furoate nasal spray : 2 sprays each nostril every morning for 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo Nasal Spray</title>
          <description>Placebo nasal spray : 2 sprays each nostril every morning for 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor has the right to review the results prior to publication of the results. But no embargo or time limit was given.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James N. Moy, M.D.</name_or_title>
      <organization>Rush University Medical College</organization>
      <phone>312-942-6176</phone>
      <email>jmoy@rush.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

